Insider Selling: bluebird bio Director Unloads 307,000 Shares of Stock (BLUE)
bluebird bio (NASDAQ:BLUE) Director Robert I. Tepper sold 307,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $22.43, for a total transaction of $6,886,010.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of bluebird bio (NASDAQ:BLUE) traded down 1.21% during mid-day trading on Friday, hitting $23.70. 168,094 shares of the company’s stock traded hands. bluebird bio has a 52-week low of $17.03 and a 52-week high of $36.25. The stock’s 50-day moving average is $21.31 and its 200-day moving average is $24.86. The company’s market cap is $560.1 million.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.25) by $0.01. The company had revenue of $6.39 million for the quarter, compared to the consensus estimate of $5.59 million. The company’s quarterly revenue was up 7417.6% on a year-over-year basis. On average, analysts predict that bluebird bio will post $-1.52 earnings per share for the current fiscal year.
bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.